Overview

Useful For
Aiding in the diagnosis of GM1 gangliosidosis, Morquio B disease, and galactosialidosis

This test is **not suitable for** carrier detection.

Genetics Test Information
Beta-galactosidase enzyme is deficient in the following conditions: GM1 gangliosidosis, Morquio syndrome B, and galactosialidosis.

Careful review of clinical findings will help distinguish between GM1 gangliosidosis and Morquio syndrome type B.

A diagnosis of galactosialidosis must be additionally demonstrated by a deficiency of neuraminidase.

Testing Algorithm
See [Lysosomal Storage Disorders Diagnostic Algorithm, Part 1](#) in Special Instructions.

Special Instructions
- [Informed Consent for Genetic Testing](#)
- [Biochemical Genetics Patient Information](#)
- [Informed Consent for Genetic Testing (Spanish)](#)
- [Lysosomal Storage Disorders Diagnostic Algorithm, Part 1](#)

Method Name
Fluorometric

NY State Available
Yes

Specimen

Specimen Type
Whole Blood ACD

Shipping Instructions
*For optimal isolation of leukocytes, it is recommended the specimen arrive refrigerated within 72 hours of collection to be stabilized.* Collect specimen Monday through Thursday only and not the day before a holiday. Specimen should be collected and packaged as close to shipping time as possible.

Necessary Information
Provide a reason for referral with each specimen.

Specimen Required

Container/Tube:
- **Preferred**: Yellow top (ACD solution B)
- **Acceptable**: Yellow top (ACD solution A)
Specimen Volume: 6 mL

Collection Instructions: Send in original tube. Do not transfer blood to other containers.

Forms
1. **New York Clients-Informed consent is required.** Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:

   - [Informed Consent for Genetic Testing](#) (T576)
   - [Informed Consent for Genetic Testing-Spanish](#) (T826)

2. **Biochemical Genetics Patient Information** (T602) in Special Instructions.

3. If not ordering electronically, complete, print, and send an [Inborn Errors of Metabolism Test Request](#) (T798) with the specimen.

Specimen Minimum Volume
5 mL

Reject Due To

<table>
<thead>
<tr>
<th>Gross hemolysis</th>
<th>Reject</th>
</tr>
</thead>
</table>

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole Blood ACD</td>
<td>Refrigerated (preferred)</td>
<td>72 hours</td>
<td>YELLOW TOP/ACD</td>
</tr>
<tr>
<td></td>
<td>Ambient</td>
<td>72 hours</td>
<td>YELLOW TOP/ACD</td>
</tr>
</tbody>
</table>

Clinical and Interpretive

Clinical Information

Beta-galactosidase is a lysosomal enzyme responsible for catalyzing the hydrolysis of gangliosides. Isolated deficiency of this enzyme is expressed clinically as 2 different diseases, GM1 gangliosidosis and Morquio syndrome B. Galactosialidosis is also associated with a deficiency of beta-galactosidase but in conjunction with neuraminidase secondary to a defect in protective protein cathepsin A (CTSA). Enzymatic testing is not reliable for carrier detection of these conditions.

GM1 gangliosidosis is an autosomal recessive lysosomal storage disorder caused by reduced or absent beta-galactosidase activity. Absent or reduced activity leads to the accumulation of GM1 gangliosides, oligosaccharides, and keratan sulfate. The disorder can be classified into 3 subtypes that vary with regard to age of onset and clinical presentation. Type 1, or infantile onset, typically presents between birth and 6 months with a very rapid progression of hypotonia, dysostosis multiplex, hepatosplenomegaly, central nervous system degeneration, and death usually by 1 to 2 years. Type 2 is generally classified as late infantile or juvenile with onset between 7 months and 3 years and presenting with developmental delays or regression and a slower clinical course. Type 3 is an adult or chronic variant with onset between 3 and 30 years and is typically characterized by slowly progressive dementia with Parkinsonian features and dystonia. The incidence has been estimated to be 1 in 100,000 to 200,000 live births.
In mucopolysaccharidosis type IVB (MPS IVB, Morquio B), reduced or absent beta-galactosidase activity leads to the accumulation of glycosaminoglycans (GAG) in lysosomes and interferes with normal functioning of cells, tissues, and organs. MPS IVB typically manifests as a systemic skeletal disorder with variable severity ranging from early severe disease to a later onset attenuated form. Virtually all patients have dysostosis multiplex and short stature along with other symptoms that may include coarse facies, hepatosplenomegaly, hoarse voice, stiff joints, cardiac disease, but no neurological involvement.

Galactosialidosis is an autosomal recessive lysosomal storage disease (LSD) caused by variants in the cathepsin A gene (CTSA) resulting in a combined deficiency of the enzymes beta-galactosidase and neuraminidase. The disorder can be classified into 3 subtypes that vary with respect to age of onset and clinical presentation. Typical clinical presentation includes coarse facial features, cherry-red spots, and skeletal dysplasia. The early infantile form is associated with fetal hydrops, visceromegaly, skeletal dysplasia, and early death. The late infantile form typically presents with short stature, dysostosis multiplex, coarse facial features, hepatosplenomegaly, and/or heart valve problems. The majority of individuals with the juvenile/adult form of GS are of Japanese ancestry and develop symptoms after 4 years of age which include neurologic degeneration, ataxia, and angiokeratomas.

Patients with mucolipidosis II/III (I-cell disease) may also demonstrate deficiency of beta-galactosidase in leukocytes, in addition to deficiency of other hydrolases. I-cell disease is an autosomal recessive lysosomal storage disorder resulting in impaired transport and phosphorylation of newly synthesized lysosomal proteins to the lysosome due to deficiency of N-acetylglucosamine 1-phosphotransferase (GlcNAc). Characteristic clinical features include short stature, skeletal and cardiac abnormalities, and developmental delay. Measurement of beta-galactosidase activity is not the preferred diagnostic test for I-cell disease, but may be included in the testing strategy.

A diagnostic workup in an individual with GM1 gangliosidosis, Morquio B, or galactosialidosis typically demonstrates decreased beta-galactosidase enzyme activity in leukocytes or fibroblasts; however, additional testing and consideration of the patient's clinical findings are necessary to differentiate between these conditions. Follow-up testing may include LYSUDU / Lysosomal Storage Disorders Screen, Random, Urine, which analyzes mucopolysaccharides, oligosaccharides, ceramide trihexosides, and sulfatides to help differentiate between the 3 conditions and guide physicians in choosing the best confirmatory molecular testing option.

Reference Values
> or =1.56 nmol/min/mg

Interpretation
Very-low enzyme activity levels are consistent with GM1 gangliosidosis and Morquio B disease. Clinical findings must be used to differentiate between those 2 diseases. The deficiency of beta-galactosidase combined with neuraminidase deficiency is characteristic of galactosialidosis.

Cautions
This test does not differentiate between GM1 gangliosidosis, Morquio B, and galactosialidosis.

Clinical Reference


**Performance**

**Method Description**


**PDF Report**

No

**Day(s) and Time(s) Test Performed**

Specimens are processed Monday through Sunday.

Assay is performed: Varies

**Analytic Time**

8 days

**Maximum Laboratory Time**

15 days

**Specimen Retention Time**

WBC homogenate stored 1 month

**Performing Laboratory Location**

Rochester

**Fees and Codes**

**Fees**

- Authorized users can sign in to **Test Prices** for detailed fee information.
- Clients without access to Test Prices can contact **Customer Service** 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact **Customer Service**.

**Test Classification**

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

**CPT Code Information**

82657
## LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BGA</td>
<td>Beta-Galactosidase, Leukocytes</td>
<td>24061-4</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>8486</td>
<td>Beta-Galactosidase, Leukocytes</td>
<td>24061-4</td>
</tr>
<tr>
<td>34979</td>
<td>Interpretation (BGA)</td>
<td>59462-2</td>
</tr>
<tr>
<td>34907</td>
<td>Reviewed By</td>
<td>18771-6</td>
</tr>
</tbody>
</table>